GleamWall
中文EN

NIKI Niki BioSolutions, Inc.

Measuring & Controlling Devices, NEC · Nasdaq · SEC CIK 1734005 · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-66.7%
TTM net income YoY71.2%
TTM EPS YoY77.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin2.4%
Operating margin—
Net margin-654.8%
FCF margin-1,791.3%
EBITDA margin—

Returns

ROE-13.9%
ROA-13.6%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets25.5%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.73x
Accruals ratio23.6%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$352,879$2.20M
SG&A expense$573,059$669,486
Pretax income-$1.38M-$4.16M
Net income-$1.36M-$4.27M
EPS (basic)-0.19-0.78
EPS (diluted)-0.19-0.78
Weighted avg. shares (diluted)7.35M5.45M
Balance sheet
Cash & equivalents$3.45M$874,238
Current assets$3.59M$959,554
Total assets$18.69M$16.13M
Current liabilities$4.59M$4.34M
Total liabilities$4.90M$4.35M
Shareholders' equity$23.12M$21.13M
Cash flow statement
Operating cash flow-$1.84M-$1.19M
Investing cash flow—$58,621
Financing cash flow$4.42M—
Depreciation & amortization—$255,046

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.